The market has been estimated at USD XX billion in 2016 and is projected to reach USD XX by 2021, at a CAGR of about X% during the forecast period from 2016 to 2021. Protein engineering is the design and construction of novel proteins or enzymes with desired properties by manipulation of their genes. The basic approaches of protein engineering are rational design, directed evolution and semi-rational design. Rational design is a computational design which requires amino acid sequence, 3D structure and functional knowledge of protein of interest. Directed evolution imitates the natural process of evolution by reducing the time frame of evolution from millions of years to few months or weeks. A combination of rational design and directed evolution gives a new approach with improved properties and function of enzymes called as semi-rational design.
Protein engineering finds application in the areas of food and detergent manufacturing, environmental bioremediation, medicine, biopolymer production, nanobiotechnology and industrially important enzyme production.
The global protein engineering market is driven by rising prevalence of protein deficient chronic diseases and the demand for alternatives to chemical processes. However, the market is constrained due to lack of experts to strategize the process and huge costs of the process.
The global protein engineering market can be segmented by end user: biotechnology companies, pharmaceutical companies, academic institutions, and contract research organisations (CRO); by product type: modified proteins, insulin, monoclonal antibodies, modified enzymes, blood factors, tissue plasminogen activator and fusion proteins; and by technology: irrational protein design and rational protein design.
The global protein engineering market has also been geographically segmented into Asia Pacific, Europe, Middle East and North Africa (MENA), North America and Rest of the World, with North America dominating the global market. Asia Pacific is also an emerging market which has a scope for growth and can potentially dominate the market in the future.
The growth of protein engineering market globally is majorly associated to the increasing prevalence of the use of protein engineering in healthcare institutes and hospitals. The major companies dominating this market with its products, services, and continuous product developments are Eli Lilly, Novo Nordisk, Roche, Biogen, Amgen, Fusion Antibodies, Genzyme, and Abbott. However, capitalisation on patents is a major challenge faced by the market players.
Key Deliverables in the Study